List view / Grid view
An advocate for genetic medicines and the enormous potential they hold, Leah Sabin at Regeneron Genetic Medicines reveals how passion and curiosity can forge the path to a rewarding career in STEM.
In mice and hamsters, therapies made from two antibodies were found to be mostly effective against a range of SARS-CoV-2 variants.
Neutralisation resistance generated by Spike (S) protein mutations in Severe Acute Respiratory Syndrome coronavirus 2 (SARS-CoV-2) poses a challenge to antibody therapies for COVID-19. Antibody cocktails targeting the S protein receptor binding domain (RBD) are one way to avoid viral neutralisation escape, however only certain antibody combinations are currently effective.…
In this article, Ian Chan, Chief Executive Officer and Co-Founder of biotech company Abpro, discusses the development of neutralising antibodies for SARS-CoV-2. Abpro’s neutralising antibody candidate ABP 300 is currently in Phase II/III trials.
At the beginning of March, US President Donald Trump pressed the pharmaceutical industry to “accelerate the development” of vaccines and therapies to contain the outbreak of the coronavirus pandemic. This article explores what is currently known about COVID-19 and potential treatments that are in the pipeline.
Researchers have discovered how the immune system might protect a person from recurrent bacterial skin infections caused by Staphylococcus aureus...
12 April 2016 | By Victoria White, Digital Content Producer
In addition to the discovery, development and commercialisation of new therapies, the companies will focus on technology development of the CRISPR/Cas platform...
3 March 2016 | By Victoria White
ANGPTL4 inhibits lipoprotein lipase (LPL), an enzyme that helps break down triglycerides, a form of fat derived from food...
10 February 2016 | By Victoria White
Regeneron has joined the Human Vaccines Project, a public-private partnership to help discover and develop new vaccines and immunotherapies...
24 September 2015 | By Victoria White
Regeneron will provide the ETI with access to VelocImmune technology to generate antibodies against targets of interest and explore potential therapeutic applications for human disease...
10 August 2015 | By Charlotte Batchelor
Court ruling further strengthens Merus’ freedom to operate in using transgenic mice for therapeutic human antibodies...
28 July 2015 | By Victoria White
Regeneron and Sanofi have entered into a new global collaboration to discover, develop and commercialise new antibody cancer treatments in immuno-oncology...
30 June 2015 | By Victoria White
A study has demonstrated that Veloci-technologies enabled rapid identification and validation of potential candidates that could be developed to treat MERS...
12 June 2014 | By Sanofi
Sanofi and Regeneron Pharmaceuticals, Inc. presented positive results from a phase 3 trial of investigational drug sarilumab in rheumatoid arthritis patients who were inadequate responders to methotrexate therapy...
